EG 427’s EG110A Gene Therapy Shows >80% Reduction in Urinary Incontinence Episodes in NDO Patients

French biotech EG 427 reported positive Phase Ib/IIa data for its EG110A gene therapy in neurogenic detrusor overactivity (NDO). Using the proprietary HERMES nrHSV-1 platform, a single treatment reduced urinary incontinence episodes by over 88% at the lowest dose by week 12, with effects apparent as early as week four.

EG110A, a non-replicating HSV-1 vector, selectively silences type C sensory neurons responsible for bladder overactivity while preserving other bladder functions. The therapy was well-tolerated, and dosing in the next cohort has begun.

EG 427 sees potential to expand this platform to other sensory neuron-driven diseases, including pain, validating a versatile biological mechanism for multiple underserved pathologies.

02-10-2025